LOS ANGELES, CA / ACCESSWIRE / November 29, 2018 / Lakewood-Amedex, a leading developer of novel anti-infective pharmaceuticals, today announced that it will be presenting at the 11th annual LD Micro Main Event on Thursday, December 6 at 11:00 AM PST / 2:00 PM EST. Steve Parkinson, CEO...
SARASOTA, Fla., Aug. 22, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today the completion of patient treatment in the final cohort of the Company's Phase 1/2a clinical trial for its lead program, topically applied Bisphosphocin Nu-3 antimicrobial, for patients...
SARASOTA, Fla., April 4, 2017 /PRNewswire/ -- Lakewood-Amedex Inc., a clinical stage pharmaceutical company developing novel anti-infectives, announced today that it is advancing its second bisphosphocin candidate toward clinical development in 2017. The Company reported new in vitro data confirming the unique mechanism of action...
SARASOTA, Fla., May 26, 2016 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has appointed Steve Miley, M.D., to serve as its Chief Medical Officer. Dr. Miley, currently a practicing physician and a member of the Company's...
SARASOTA, Fla., May 19, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that a recent series of in vitro studies conducted by Southern Research in Birmingham, Alabama, have demonstrated that its novel class of antimicrobials, named bisphosphocins, have proven...
SARASOTA, Fla., March 12, 2015 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has expanded upon a research collaboration with Dr. Leona Gilbert at the Department of Biological and Environmental Sciences of the University of Jyvaskyla, Finland to...
SARASOTA, Fla., Dec. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced that the Company has submitted an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) to conduct a Phase 1/2a study of Nu-3 as a...
SARASOTA, Fla., Sept. 11, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that the United States Patent and Trademark Office has issued a 'Notice of Allowance' for patent application 11/673,486 entitled 'Oligonucleotide-Containing Pharmacological Compositions And Their Uses'. The...
SARASOTA, Fla., June 18, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has raised a total of $5.5 million, before fees and expenses, through a Series C Preferred stock offering from a group of accredited investors. ...
SARASOTA, Fla., Jan. 8, 2014 /PRNewswire/ -- Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today that it has elected Geoffrey F. Cox, Ph.D., to serve on its board of directors. Dr. Cox, currently an independent consultant to the Biotechnology and Life...